Novartis discontinues Phase 2 ALS trial after failed endpoints
Novartis said its Phase 2 ALS treatment VHB937 did not meet primary or secondary endpoints and the company will discontinue development.
Novartis said its Phase 2 trial of an ALS treatment did not meet its primary or secondary endpoints. The drugmaker said Wednesday it has decided to discontinue development of VHB937 in ALS. The trial's end follows a string of setbacks for Novartis this month.